News | January 04, 2022
Domestic and emerging markets will drive pharma growth: ICRA
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
During H1 FY2022, the revenues and operating profit margin (OPM) for ICRA sample set showed sharp improvement aided by volume uptick in Covid-19 and allied tests and also demand traction for non-Covid tests
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
A total of 12 generic medicines have been included in the list
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
Subscribe To Our Newsletter & Stay Updated
